Could a common eye drop speed up wound healing after skin cancer surgery?
NCT ID NCT07384767
First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times
Summary
This study tests whether a topical timolol solution, normally used as eye drops, can help skin wounds heal faster when left open after surgery. 220 adults who choose to let their surgical wounds heal naturally will apply either timolol or a placebo gel daily for 12 weeks. Researchers will compare wound closure and infection rates between the two groups.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- timolol 0.5% ophthalmic solution
- What this could lead to
- If it works, this could offer a simple, low-cost way to help skin wounds heal faster after surgery without needing stitches.
- What could go wrong
- This is an early phase 2 trial, so results are not yet proven. The benefit may be small or no different from standard care, and daily application for 12 weeks may be inconvenient.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 220 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female subject of any race 18 years old or older 2. Patient opt to heal by secondary intention healing after discussion of reconstructive options following excision 3. Patients undergoing Mohs micrographic surgery, standard surgical excision, or electrodesiccation and curettage (ED\&C) whose wounds are managed by secondary intention healing. 4. Willing to send photos of ulcer at 3 week intervals with ruler measuring length by width 5. Able to give informed consent themselves Exclusion Criteria: 1. Cyst excisions (due to concern for inflammation) 2. Site shows evidence of infection (defined as a moderate or severe rating of all of the following clinical signs/symptoms: 1) increased warmth, 2) increased pain, 3) erythema, and 4) malodorous exudate at Screening or at Randomization (Visit 1), OR total organism count \> 1 x 105 colony forming units (CFU) from the screening visit study ulcer culture sample) 3. Severe COPD/asthma/cardiac arrhythmia 4. Hx of documented beta blocker allergy 5. Cognitive impairment 6. Has medically documented history of Human Immunodeficiency Virus (HIV) 7. Has active malignancy on the study limb 8. Has immunodeficiency as defined by serum IgG, IgA, and IgM less than one-half the lower limit of normal 9. Has severe protein malnutrition as defined by serum albumin \< 2.5 g/dL 10. Has serum aspartate aminotransferase (AST, SGOT, GOT) or serum alanine aminotransferase (ALT, SGPT, GPT) levels greater than twice the upper limit of normal 11. Has fatigue, palpitations, dyspnea, and/or angina at rest 12. Has a medically documented or self-reported history, within the previous 12 months from date of Screening Visit, of alcohol or drug abuse, particularly methadone or heroin 13. Has received previous treatment with the following during the 60 days prior to Screening: Immunosuppressive agents, radiation, chemotherapy, growth factors (epidermal growth factor, tumor necrosis factor, transforming growth factor, platelet derived growth factor, etc.) 14. Has received previous treatment with the following during the 30 days prior to screening: the site of the study ulcer, split- or full-thickness skin graft at the site of the study ulcer, biologically-active (or engineered) cellular or acellular product(s) at the site of the study ulcer, investigational drug or device 15. Has history of bradycardia (heart rate less than 60) 16. Has ESR\>70mm/hr and CRP\>100 mg/L at time of screening 17. Has medically documented history of hypotension/orthostatic hypotension and/or symptomatic hypotension (systolic blood pressure below 90 and diastolic blood pressure less than 60). (Note: There is no standard testing regimen protocol for orthostatic hypotension, even for patients starting on oral timolol) 18. Currently taking asthma or COPD medications (as documented in chart) 19. Has a medically documented diagnosis of myasthenia gravis, untreated hyperthyroidism, , Type 2, Type 3 heart block, cardiogenic shock, overt cardiac failure 20. Female who is pregnant or refuses to use adequate contraceptive methods and is of childbearing age during the trial 21. Prisoners, institutionalized individuals or vulnerable population
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Excision margin are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UC Davis Health- Dermatology
Sacramento, California, 95816, United States
-
VA Medical Center- Sacramento
Sacramento, California, 95655, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.